Clinical trials showed that beginning 2 weeks after the second dose, the Moderna Spikevax ® COVID vaccine was: A severe allergic (anaphylaxis) reaction is also rare. Signs and symptoms of anaphylaxis may include: A different vaccine may be offered for your second dose. For example, you may have received Pfizer-BioNTech Comirnaty ® as your first dose and be offered Moderna Spikevax ® as your second. This is known as a mixed vaccine series. Find detailed technical information such as the product monograph and the regulatory decision summary: Dose volume depends on which series of the vaccine is being administered. The dose for people 12 years of age and older (100 micrograms) is:

After getting vaccinated, it's common to have temporary side effects. These can last a few hours to a few days after vaccination. Reported allergic reactions and side effects to COVID-19 vaccines are published weekly in our Reported side effects following COVID-19 vaccination report. Vaccine review, approval and monitoring The Moderna Spikevax®Monovalent COVID-19 vaccine(Omicron XBB.1.5 subvariant) is approved for people who are 6 months of age and older. It may be given to people who have been previously vaccinated or who have not been previously vaccinated. As COVID-19 vaccines are administered across Canada, our safety monitoring is ongoing. The Public Health Agency of Canada, Health Canada, and provincial and territorial health authorities continue to:Health Canada's independent drug review process is recognized around the world for its high standards and rigor. Our decisions are based only on scientific and medical evidence showing that vaccines are safe and effective. The benefits must also outweigh any risks. The mRNA sequence from Moderna Spikevax ® COVID-19 vaccine is also included in the Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1). The bivalent booster also has an additional mRNA sequence that targets the Omicron BA.1 variant.

months to 4 years (25 micrograms at least 6 months after their previous dose). If the child has not been previously vaccinated, Spikevax XBB.1.5 should be administered a 2-dose regimen. The Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.1) is approved as a booster for people who are 6 years of age and older. Its safety and effectiveness in younger people has not yet been established. Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) to 11 years (25 micrograms at least 6 months after their previous dose) Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1), Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) Omicron XBB.1.5 subvariant vaccine dosesyears and older (50 micrograms at least 4 months after their previous dose) Moderna Spikevax ®COVID-19 vaccine, Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1), Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) The mRNA sequence from Moderna Spikevax ®COVID-19 vaccine is also included in the Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5). The bivalent booster also has an additional mRNA sequence that targets the Omicron BA.4/5 variants. Other ingredients The Moderna Spikevax ® COVID-19 vaccine is approved for primary vaccination in people who are 6 months of age and older. Its safety and effectiveness in people younger than 6 months have not yet been established. This vaccine is also approved as a booster for people 12 years of age and older. Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1) The bivalent Original/Omicron BA.4/5 0.1 mg/mL multi-dose vial has a royal blue plastic cap and grey label.

The bivalent Original/Omicron BA.1 0.1 mg/mL multi-dose vial has a royal blue plastic cap and green label. Its safety and effectiveness in people younger than 6 months has not yet been established. EffectivenessThe Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) is approved as a booster for people who are 6 years of age and older. Its safety and effectiveness in younger people has not yet been established. Moderna Spikevax ®Monovalent COVID-19 vaccine (Omicron XBB.1.5 subvariant) The Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1) was shown to increase the immune response against the Omicron BA.1 variant. This means that the booster is expected to offer protection against this variant. Health care providers must report possible reactions following vaccination to their local public health authority. The public health authority then reports them to the Public Health Agency of Canada. The safety and effectiveness of the Moderna Spikevax® Monovalent COVID-19 vaccine (Omicron XBB 1.5) is based on studies of Spikevax® (Original, Original/Omicron BA.1 & XBB.1.5). Dosage Primary series

The monovalent Omicron XBB 1.5 subvariant multi-dose vial has a royal blue plastic cap and coral blue label. The National Advisory Committee on Immunization (NACI) recommends an mRNA vaccine (Pfizer-BioNTech Comirnaty ® or Moderna Spikevax ®) should be offered for your second dose. thanks for the tremendous contribution slewman. out of interest where did you get all the colours from? The safety and effectiveness of the Moderna Spikevax ® Bivalent COVID-19 vaccine(Original/Omicron BA. 4/5) is based on studies of Spikevax ® Bivalent (Original/Omicron BA.1). Call emergency services if you develop or witness any serious symptoms that could be anallergic reactionafter vaccination. Reporting a possible serious reaction

Your province or territory decides when people receive their doses of the vaccine. These decisions are based on public health recommendations and the latest evidence. Primary series in individuals age 6 months and older, or as a booster dose in individuals age 12 years and older: